5-(2-bromophenyl)-7-fluoro-1,3-dihydro-1,4-benzodiazepine-2-one | 153873-96-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-1,4-benzodiazepine-2-one
• 英文别名: 5-(2-Bromophenyl)-7-fluoro-1,3-dihydro-1,4-benzodiazepin-2(2H)-one；5-(2-Bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one；5-(2-bromophenyl)-7-fluoro-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 153873-96-2
• 化学式: C₁₅H₁₀BrFN₂O
• 分子量: 333.16
• InChiKey: APTIFBSTEIXFOB-UHFFFAOYSA-N

物化性质

• 沸点：
  468.4±45.0 °C(Predicted)
• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-bromophenyl)-7-fluoro-1,3-dihydro-1,4-benzodiazepine-2-one 在 盐酸 、 ammonium hydroxide 、 五氯化磷 、 potassium tert-butylate 、 氯磷酸二乙酯 作用下， 反应 27.75h， 生成 米达西尼
  参考文献：
  名称：

  Synthesis of iodine-123 labelled analogues of imidazenil and ethyl-imidazenil for studying benzodiazepine receptors using SPECT

  摘要：

  DOI：

  10.1002/(sici)1099-1344(199612)38:12<1121::aid-jlcr948>3.0.co;2-v
• 作为产物：
  描述：

  (2-amino-5-fluorophenyl)(2-bromophenyl)methanone 在 氨 、 碳酸氢钠 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-1,4-benzodiazepine-2-one
  参考文献：
  名称：

  Tetrazole derivatives bearing benzodiazepine moiety—synthesis and action mode against virulence of Candida albicans

  摘要：

  DOI：

  10.1016/j.ejmech.2021.114060

文献信息

• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DES RÉCEPTEURS 5-HT2C, COMPOSITIONS ET MÉTHODES D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2018035477A1

  公开（公告）日：2018-02-22

  The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a 5-HT2C receptor-mediated disorder, such as, weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction and the like, obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders, urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a compound herein, optionally in combination with a supplemental agent.

  本发明涉及式A的化合物及其药物组合物，可调节5-HT2C受体的活性。本发明的化合物及其药物组合物用于治疗5-HT2C受体介导的疾病，如体重管理、诱发饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾等，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停症。还提供含有本文中化合物的组合物，可选择性地与辅助剂组合使用。
• Benzodiazepines and compositions for treating anxiety and panic
  申请人：——

  公开号：US05317018A1

  公开（公告）日：1994-05-31

  The present invention is directed to imidazo[1,5-a][1,4]benzodiazepine-3-carboxamide compounds of the formula: ##STR1## wherein R is hydrogen, C.sub.3 CH.sub.2 --, CH.sub.2 .dbd.CHCH.sub.2 --, (CH.sub.3).sub.2 CH--, CH.sub.3 CH.sub.2 CH.sub.2 --, or ##STR2## or a pharmaceutically acceptable salt thereof. These compounds and their pharmaceutically acceptable salts possess anti-anxiety and anti-epileptic activity.

  本发明涉及公式为：##STR1## 的咪唑[1,5-a][1,4]苯二氮平-3-羧酰胺化合物，其中R为氢、C.sub.3 CH.sub.2 --、CH.sub.2 .dbd.CHCH.sub.2 --、(CH.sub.3).sub.2 CH--、CH.sub.3 CH.sub.2 CH.sub.2 --或##STR2##，或其药学上可接受的盐。这些化合物及其药学上可接受的盐具有抗焦虑和抗癫痫活性。
• Benzodiazepines and their compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0573982A1

  公开（公告）日：1993-12-15

  The present invention is directed to imidazo[1,5-a] [1,4]benzodiazepine-3-carboxamide compounds of the formula:    wherein R is hydrogen, CH₃CH₂-, CH₂=CHCH₂-, (CH₃)₂CH-, CH₃CH₂CH₂-, or or a pharmaceutically acceptable salt thereof. These compounds and their pharmaceutically acceptable salts possess anti-anxiety and anti-epileptic activity.

  本发明涉及式中的咪唑并[1,5-a][1,4]苯并二氮杂卓-3-甲酰胺化合物： 其中 R 是氢、CH₃CH₂-、CH₂＝CHCH₂-、(CH₃)₂CH-、CH₃CH₂CH₂-，或 或其药学上可接受的盐。这些化合物及其药学上可接受的盐具有抗焦虑和抗癫痫活性。
• 5-HT2C receptor agonists and compositions and methods of use
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10272094B2

  公开（公告）日：2019-04-30

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在一些实施方案中，提供了如本文所定义的式 A 化合物，其可调节 5-HT2C 受体的活性。在一些实施方案中还提供了一些方法，例如，用于体重管理、诱导饱腹感和减少食物摄入量，以及预防和治疗肥胖症、抗精神病药诱导的体重增加、2 型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病态赌博、奖赏缺乏综合征和性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和嗜睡）、睡眠障碍（包括失眠、睡眠结构破碎和慢波睡眠紊乱）、尿失禁、精神障碍（包括精神分裂症、神经性厌食症和神经性贪食症）、老年痴呆症、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物诱发的运动障碍）、高血压、血脂异常、非酒精性脂肪肝、肥胖相关性肾病和睡眠呼吸暂停。
• THERAPEUTIC DOSING OF A NEUREGULIN OR A FRAGMENT THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
  申请人：Acorda Therapeutics, Inc.

  公开号：EP2964249A1

  公开（公告）日：2016-01-13